内分泌治疗联合加速部分乳腺照射或单独超加速部分乳腺照射用于≥60岁早期乳腺癌(EPOPE):GEC-ESTRO随机III期试验的理论依据
EPOPE试验针对≥60岁低风险Luminal A型早期乳腺癌患者,比较APBI联合5年内分泌治疗与单独uAPBI(16 Gy单次)的非劣效性。文中综述显示大分割放疗局部控制非劣于标准分割,APBI除术中技术外局部控制非劣于全乳照射,uAPBI二期结果令人鼓舞,而单独内分泌治疗不联合放疗显著增加局部复发率但不影响总生存。
要点
- ≥60岁低风险Luminal A型早期乳腺癌为EPOPE试验目标人群。
- 试验比较APBI+5年内分泌治疗与单独uAPBI(16 Gy单次)的疗效。
- 二期uAPBI肿瘤学结局与毒性结果令人鼓舞,支持开展III期试验。
核心结论
- EPOPE III期随机试验旨在评估老年低风险乳腺癌的降阶梯辅助治疗策略,比较APBI联合5年内分泌治疗与单独uAPBI(16 Gy单次)的疗效。
研究设计与样本
- 本文为GEC-ESTRO乳腺癌工作组支持的III期随机对照试验的理论依据阐述,目标人群为≥60岁低风险Luminal A型乳腺癌患者。
主要发现
- III期随机试验证实加速或非加速大分割方案在局部控制方面非劣于标准分割方案。
- 除术中技术外,APBI在低风险乳腺癌中的局部控制率非劣于全乳照射。
- 二期前瞻性试验中uAPBI在肿瘤学结局和毒性方面结果令人鼓舞。
- III期试验中单独内分泌治疗不联合放疗显著增加局部复发率,但不影响总生存,而单独放疗有效。
关键数值与推荐
- EPOPE试验比较APBI联合5年内分泌治疗与单独uAPBI(16 Gy单次)两种方案。
临床怎么用
- 为老年低风险早期乳腺癌患者提供降阶梯辅助治疗选择的循证依据,待EPOPE试验结果明确APBI联合内分泌治疗与单独uAPBI的优劣。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Breast cancer in the elderly has become a public health concern; there is a need to re-design its treatment with a view to de-escalation. Our paper sets out the rationale for a phase 3 randomized trial to evaluate less burdensome adjuvant procedures that remain effective and efficient. MATERIALS AND METHODS: For low-risk breast cancer in the elderly, adjuvant treatment has been adjusted in order to make it more suitable and efficient. Hypofractionated radiation therapy based on accelerated or non-accelerated regimens as well as accelerated and ultra-accelerated partial breast irradiation (APBI) protocols were reviewed. Withdrawal of radiation (RT) or endocrine therapies (ET) from the adjuvant procedure were also investigated. Based on molecular and APBI classifications, inclusion criteria were discussed. RESULTS: Phase 3 randomized trials which compared standard vs. accelerated/non-accelerated hypofractionated regimens confirmed that the latter were non-inferior in terms of local control. Similarly, except for intraoperative-based techniques, APBI achieved non-inferior local control rates compared to whole breast irradiation for low-risk breast cancer. In phase 2 prospective trials using ultra APBI, encouraging results were observed regarding oncological outcome and toxicity profile. In phase 3 trials, adjuvant ET without RT significantly increased the rate of local relapse with no impact on overall survival while RT alone proved effective. Elderly patients aged 60 or more with low-risk, luminal A breast cancer were chosen as the target population in a phase 3 randomized trial comparing APBI + 5-year ET vs. uAPBI (16 Gy 1f) alone. CONCLUSION: To investigate de-escalation adjuvant treatment for elderly breast cancer patients, we have defined a road map for testing more convenient strategies. This EPOPE phase 3 randomized trial is supported by the GEC-ESTRO breast cancer working group.
引用
- Hannoun-Levi JM, Chamorey E, Boulahssass R, et al. Endocrine therapy with accelerated Partial breast irradiatiOn or exclusive ultra-accelerated Partial breast irradiation for women aged ≥ 60 years with Early-stage breast cancer (EPOPE): The rationale for a GEC-ESTRO randomized phase III-controlled trial. Clin Transl Radiat Oncol. 2021. PMID: 33997321. doi:10.1016/j.ctro.2021.04.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。